Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.



What is ASPRE?

ASPRE is the largest multicenter trial to be conducted on the prophylactic use of low-dose aspirin in women at increased risk for preterm pre-eclampsia. Funded by the EU and administered by the Fetal Medicine Foundation, ASPRE has recruited more than 33,000 pregnancies in Europe. The first results are expected to be available in 2016.

Who is Taking Part in the Study?

More than 10 hospitals from UK, Belgium, Italy, Spain, Greece and Israel will be taking part in ASPRE. Screening for preterm PE at 11-13 weeks' gestation will include a combination of maternal medical history and characteristics, maternal serum PAPP-A, and PlGF, MAP and uterine artery PI.

Women who have been identified to be at high-risk for preterm PE based on the screening test result are offered an opportunity to take part in the aspirin vs. placebo trial. Study subjects will take one tablet per night of either aspirin 150 mg or matching placebo tablet until 36-37 weeks of pregnancy.

Solutions for Pre-eclampsia Screening

PerkinElmer has been chosen as the principal screening partner for ASPRE. Throughout the study, the PerkinElmer DELFIA® Xpress PlGF 1-2-3 assay* will be used as an aid in screening for pre-eclampsia in conjunction with maternal history and mean arterial blood pressure (MAP) measurement.

The DELFIA® Xpress PlGF 1-2-3 screening assay is

  • The outcome of intense research and collaboration with leading experts in fetal medicine
  • Placental growth factor (PlGF) assay with superior sensitivity to be used as an aid in screening pregnant women for early-onset pre-eclampsia. 1

For more information on the project progress and to read our ASPRE Newsletters, please visit


  1. Hanses et al. (2014): Poster (Performance of a next generation PlGF 1-2-3 assay) at XXIV European Congress of Perinatal Medicine, Florence, June 2014.

*PerkinElmer product mentioned here is not available in the USA and Japan. Prior to registration, product is not available in China, Canada, certain Latin American countries and certain Asian countries. Please contact your country representative for further details.

*PerkinElmer does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations please consult your local health care professionals..